Get up-to-date on the most recent data presented on CLL and CML treatment from the 2017 American Society of Clinical Oncology (ASCO) annual meeting.
Three important studies presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting will likely impact initial management of patients with melanoma with asymptomatic brain metastases.
Alectinib, the optimal first-line therapy for ALK-positive NSCLC. In the global, randomized phase III ALEX study (Abstract LBA9008) involving 303 previously untreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC), the anaplastic lymphoma kinase (ALK) inhibitor alectinib (600 mg twice daily) compared with crizotinib (250 mg twice daily) reduced the risk of progression or… » Read More
Two large trials (LATITUDE and STAMPEDE), presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that upfront treatment with abiraterone plus prednisone and androgen deprivation therapy (ADT) in hormone-sensitive metastatic prostate cancer improves overall survival compared to ADT alone. These results will likely led to immediate practice change. According to… » Read More
• Using risk-based approach to personalize adjuvant chemotherapy duration for stage III colon cancer. According to a prospective pooled analysis of six phase III adjuvant colon cancer clinical trials with 12,800 patients, a 3-month course of adjuvant combination chemotherapy of oxaliplatin and intravenous 5-fluorouracil (FOLFOX) or oxaliplatin and oral capecitabine (CAPOX) has similar efficacy and… » Read More
The American Society of Clinical Oncology (ASCO) Annual Meeting was held this past week in Chicago and below we have summarized some of the eagerly awaited results of phase III clinical trials in breast cancer. Olaparib Superior to Chemotherapy in BRCA-Associated Metastatic Breast Cancer According to results from the phase III OlympiAD trial presented by… » Read More
In May, the US Food and Drug Administration (FDA) granted four new indications to the programmed death receptor-1 (PD-1) inhibitor pembrolizumab (Keytruda®, Merck). These new indications included first-line treatment of nonsquamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, second-line treatment of advanced urothelial cancer, first-line treatment of urothelial cancer in cisplatin-ineligible patients, and… » Read More
On the last days of April, the US Food and Drug Administration (FDA) approved three new indications for the treatment of patients with advanced cancer, including hepatocellular carcinoma (HCC), anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and FLT3-positve acute myeloid leukemia (AML).
The American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held at the McCormick Place Convention Center in Chicago from June 2-6, is fast approaching. According to the organizer, more than 38,000 participants from around the globe are expected to discuss the latest clinical trials updates and new research findings in oncology, state-of-the-art… » Read More
Inhibitors of programmed death receptor 1 (PD-1) are associated with significant improvements in overall survival (OS) and durable responses in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). However, a retrospective analysis from four French centers found that approximately one third of patients with recurrent and/or metastatic SCCHN treated… » Read More